Denise K. Bonney

Oxford Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

Journal: Blood advances

Published: May 07, 2026

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Journal: Leukemia

Published: October 06, 2025

Acyclovir-Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series.

Acyclovir-Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: October 02, 2025

Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome.

Farber's Lipogranulomatosis: Multimodal Therapy With Tocilizumab and Consolidative HSCT Improves Assessment, and Long-Term Outcome.

Journal: JIMD reports

Published: June 02, 2025

Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation.

Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation.

Journal: Pediatric transplantation

Published: May 13, 2025

Donor T-cell and myeloid chimerism is higher after cord blood transplant than with other cell sources.

Donor T-cell and myeloid chimerism is higher after cord blood transplant than with other cell sources.

Journal: Cytotherapy

Published: April 26, 2025

Mixed T-Cell Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders Is Common, Facilitates Anti-Viral Immunity, and Is Not Associated with Graft Failure in Pediatric Patients.

Mixed T-Cell Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders Is Common, Facilitates Anti-Viral Immunity, and Is Not Associated with Graft Failure in Pediatric Patients.

Journal: Cells

Published: October 20, 2024

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.

Journal: Blood cancer journal

Published: August 21, 2024

Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.

Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: December 05, 2023

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.

Journal: Blood cancer journal

Published: December 01, 2023

Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.

Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 15, 2023

Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts.

Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts.

Journal: Transplantation and cellular therapy

Published: September 09, 2023

Showing 1-12 of 53

Last Updated: 09/26/2026